Low-Dose Atropine for Myopia Control: What Parents Need to Know

The Evidence Behind Low-Dose Atropine

The landmark ATOM and LAMP clinical trials established atropine as an effective myopia control intervention. The LAMP study found that 0.05% atropine achieved approximately 67% reduction in myopia progression — the best balance of efficacy and tolerability, with minimal rebound effect when discontinued.

How It's Used

One drop in each eye at bedtime, nightly. The timing means any mild pupil effect resolves overnight. At concentrations of 0.01%–0.05%, most children experience no perceptible side effects during the day. Atropine for myopia control is a compounded medication — we work with reliable compounding pharmacies that produce it in accurate concentrations.

Combining With Other Treatments

Atropine and Ortho-K work through completely different mechanisms and provide additive benefit when combined. We use this combination for children with rapid progression or high genetic risk (both parents myopic). Atropine also combines well with MiSight daily disposable lenses for children who prefer daytime correction.

Monitoring and Duration

We measure axial length at every myopia control visit to objectively assess whether treatment is working. Treatment typically continues through the teenage years until myopia stabilizes — usually in the early 20s. We reassess the plan periodically and adjust concentration or approach based on the data.

Ask us about low-dose atropine at your next visit: (845) 255-4696 or book online.